Sweden · Delayed Price · Currency is SEK Ascelia Pharma AB Earnings Call Transcripts
Fiscal Year 2026
-
Major milestones are approaching with an FDA decision on Orviglance expected in early July and active partnering discussions underway. Orviglance targets a significant unmet need in liver imaging for cancer patients with renal disease, supported by strong clinical data and orphan drug exclusivity.
-
Q1 saw steady operating losses and a strengthened cash position after a SEK 20 million raise. Orviglance is on track for FDA approval in July, with strong clinical data and active partnership discussions. Market trends favor non-gadolinium agents, supporting a positive outlook.
-
Q1 2026 saw progress toward FDA approval and commercialization of Orviglance, with strong clinical data and an extended cash runway into 2027 after a SEK 20 million share issue. Oncoral remains in the pipeline with phase II plans in gastric cancer.
-
Orviglance, a manganese-based liver MRI agent for patients with severe renal disease, is under FDA review with a July 3 PDUFA date and strong Phase 3 data. Commercialization will rely on partnerships, and the company is also advancing Oncoral, an oral irinotecan, into further development.
Fiscal Year 2025
-
Lead program Orviglance is in FDA review with a decision expected by July, targeting a significant unmet need in liver imaging for cancer patients with severe renal impairment. Financials show a SEK 16 million Q4 loss and SEK 50 million cash, with partnership discussions and launch preparations progressing well.
-
Orviglance is on track for FDA approval in July 2026, targeting an $800M global market for liver MRI contrast in cancer patients with severe kidney impairment. Q4 saw a SEK 16M operating loss, SEK 15M in liquid assets, and ongoing partnering discussions for commercialization.
-
Orviglance, a manganese-based MRI contrast agent for patients with severe renal impairment, is under FDA review with a July 3rd decision expected, targeting a significant unmet need and $800M global market. Commercialization will be partner-driven, while Oncoral, an oral cancer therapy, advances toward clinical trials.
-
A novel manganese-based imaging agent for liver cancer is nearing FDA approval, offering a safer alternative to gadolinium for patients with kidney issues. Clinical trials show improved detection of small lesions and a strong safety profile, with commercialization plans underway.
-
NDA for Orviglance submitted, targeting FDA approval for liver MRI in high-risk patients. SEK 30M raised and convertibles converted, extending runway into Q4 next year. Focus remains on securing a commercialization partner and preparing for a U.S. launch.
-
OrbiGlans NDA was submitted to the FDA, with approval expected by July 2026, targeting a $800M market for liver imaging in cancer patients with renal impairment. Financials show a SEK 15M Q3 loss and SEK 72M cash, with a strengthened balance sheet and ongoing partner discussions.
-
NDA submission for Orviglance is imminent, with strong clinical results and a clear commercialization strategy focused on partnering. Financial position is stable through year-end, supported by recent warrant proceeds and loan repayment.
-
NDA submission for Orviglance is imminent, supported by strong clinical data and robust financials, with SEK 60 million in cash and a clear commercialization strategy focused on partnerships. Oncoral's phase II start depends on securing sufficient partnering funds.
-
Orviglance advances toward FDA submission with strong phase 3 data and positive regulatory feedback, targeting an $800M market. Financial runway extends to end-2024 after a successful SEK 43M warrant exercise, with commercialization partnerships and alternative financing under active consideration.
-
Orviglance is on track for NDA submission in August 2025, supported by strong phase III data and a robust financial position after a successful warrant exercise. Partnering discussions for commercialization are advancing, with the U.S. prioritized for launch.
-
Orviglance, a manganese-based MRI agent for patients with severe renal disease, is on track for NDA submission mid-year after strong phase III results. Commercialization will be through a partner, targeting a focused U.S. market segment, while industry trends favor safer, non-gadolinium agents.
Fiscal Year 2024
-
Orviglance completed phase III with strong results and is on track for NDA submission mid-2025, targeting a significant unmet need in liver imaging for cancer patients with kidney impairment. Financials show a Q4 loss and a solid cash runway, with commercialization and partnering progressing.
-
Orviglance achieved positive phase III results and is advancing toward NDA submission, supported by a fully subscribed SEK 105M rights issue that extends the cash runway to late 2025. Commercialization and partnering discussions are ongoing, with Oncoral set for phase II in gastric cancer.
-
Strong Phase 3 results for Orviglance set the stage for NDA submission and commercialization, supported by a SEK 105 million rights issue. Q2 saw reduced losses and ongoing partnering discussions, with a focus on regulatory milestones and launch readiness.
-
The presentation highlighted strong phase III results for Orviglance, a novel oral diagnostic for cancer patients with renal disease, with NDA submission targeted for mid-2025. Commercialization efforts focus on the U.S. market, while Oncoral's development will proceed as resources allow.